Immunotherapy: Some PDE5 inhibitors, such as PD-1/PD-L1, alter immune checkpoint pathways to increase the efficacy of immunotherapies for the treatment of advanced cancers such as HCC (Hao et al., 2023[49]). Here, PDE5A is linked to cancer.